If you were to ask many market players, hedge funds are viewed as useless, old investment vehicles of an era lost to time. Although there are over 8,000 hedge funds in operation in present day, this site aim at the top tier of this group, about 525 funds. Analysts calculate that this group oversees the majority of the hedge fund industry’s total capital, and by tracking their best equity investments, we’ve figured out a number of investment strategies that have historically outstripped the S&P 500. Our small-cap hedge fund strategy outstripped the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have outperformed the S&P 500 index by 33 percentage points in 11 months (explore the details and some picks here).
Equally as necessary, bullish insider trading sentiment is a second way to look at the investments you’re interested in. Obviously, there are lots of stimuli for an insider to cut shares of his or her company, but only one, very obvious reason why they would buy. Various academic studies have demonstrated the market-beating potential of this method if piggybackers understand what to do (learn more here).
Keeping this in mind, we’re going to analyze the latest info for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Hedge fund activity in Integra Lifesciences Holdings Corp (NASDAQ:IART)
At the end of the second quarter, a total of 7 of the hedge funds we track held long positions in this stock, a change of -46% from the first quarter. With the smart money’s capital changing hands, there exists a select group of notable hedge fund managers who were increasing their holdings significantly.
According to our 13F database, Ken Fisher’s Fisher Asset Management had the most valuable position in Integra Lifesciences Holdings Corp (NASDAQ:IART), worth close to $22.2 million, accounting for 0.1% of its total 13F portfolio. Coming in second is Kevin Kotler of Broadfin Capital, with a $18.4 million position; the fund has 3.6% of its 13F portfolio invested in the stock. Some other hedge funds that are bullish include David Dreman’s Dreman Value Management, James E. Flynn’s Deerfield Management and Ken Griffin’s Citadel Investment Group.
As Integra Lifesciences Holdings Corp (NASDAQ:IART) has faced a fall in interest from the entirety of the hedge funds we track, it’s easy to see that there lies a certain “tier” of funds that slashed their positions entirely heading into Q2. Intriguingly, Phill Gross and Robert Atchinson’s Adage Capital Management cut the largest position of the “upper crust” of funds we monitor, comprising close to $13.9 million in stock, and Mark Broach of Manatuck Hill Partners was right behind this move, as the fund cut about $7.5 million worth. These transactions are important to note, as total hedge fund interest fell by 6 funds heading into Q2.
How are insiders trading Integra Lifesciences Holdings Corp (NASDAQ:IART)?
Insider buying made by high-level executives is most useful when the company in question has experienced transactions within the past half-year. Over the latest half-year time frame, Integra Lifesciences Holdings Corp (NASDAQ:IART) has experienced zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).
We’ll go over the relationship between both of these indicators in other stocks similar to Integra Lifesciences Holdings Corp (NASDAQ:IART). These stocks are HeartWare International Inc (NASDAQ:HTWR), ICU Medical, Incorporated (NASDAQ:ICUI), Insulet Corporation (NASDAQ:PODD), Endologix, Inc. (NASDAQ:ELGX), and DexCom, Inc. (NASDAQ:DXCM). This group of stocks belong to the medical instruments & supplies industry and their market caps match IART’s market cap.